Is retatrutide safe? In controlled phase 3 trials, retatrutide’s side effects were mostly stomach-related, usually mild to moderate, and in line with other drugs in its class.[3][6] But it is not FDA-approved, its long-term safety is still being studied, and products sold outside Lilly’s trials are of unknown quality.[10] So the honest answer is: reasonably well tolerated in trials, unproven in the long term, and unknowable outside a trial.

This page sets out what the trials do show, what they cannot show yet, and where the real risks lie. For background, see the retatrutide profile.

How much safety data exists?

The phase 3 TRIUMPH program enrolled more than 5,800 people across four trials.[8] The main trials lasted 68 to 80 weeks, and a TRIUMPH-1 extension followed 532 selected participants to 104 weeks.[2] Separate phase 3 diabetes trials (TRANSCEND) add more.[6]

That is a large evidence base for a drug not yet approved. It is still small compared with what exists for drugs that have been on the market for years, and rare side effects may only become clear once many more people use a drug.

What the trials do tell us

Stomach side effects are common but mostly manageable

Nausea, diarrhea, constipation and vomiting were the most frequent problems and rose with dose. In TRIUMPH-1, nausea affected 28.6% to 42.4% of people on retatrutide versus 14.8% on placebo.[2] In TRANSCEND-T2D-1, stomach effects were mostly mild to moderate and eased over time.[6] Starting at a low dose and stepping up helped: in phase 2, a 2 mg start partly reduced these effects compared with 4 mg.[7]

More people stopped at higher doses

The share who stopped because of side effects in TRIUMPH-1 was 4.1%, 6.9% and 11.3% on 4, 9 and 12 mg, versus 4.9% on placebo.[2] In TRIUMPH-4 it reached 18.2% on 12 mg; Lilly said this tracked with starting weight and included people who felt they had lost too much weight.[5]

Some side effects stand out

  • Dysesthesia (tingling, burning or sensitive skin) was reported in 4% to 21% of people on retatrutide depending on dose and trial, versus about 1% on placebo. Lilly said most cases were mild to moderate and resolved during treatment.[2][3][5]
  • Low blood pressure was more common than with placebo in people with type 2 diabetes: up to 6% on 12 mg versus under 1%.[3]

Our guide to retatrutide side effects has the full numbers by dose.

Deaths were rare and judged unrelated

In TRIUMPH-2, seven people died across all groups, one of them on placebo. In TRANSCEND-T2D-1, two people died, both on 4 mg. In each trial, investigators judged none of the deaths related to retatrutide.[3][6]

Heart safety: mixed signals

  • Heart rate: in the phase 2 trial, heart rate rose with dose, peaked at 24 weeks and then declined.[7]
  • Risk factors improved: in TRIUMPH-3, among adults with heart disease, 12 mg lowered triglycerides by 37.0%, systolic blood pressure by 9.3 mmHg and the inflammation marker hsCRP by 51.2%.[4]
  • Heart events: in the same trial, 44 people on retatrutide and 52 on placebo had a broad heart event (MACE-5), but for the narrower heart attack, stroke or cardiovascular death measure the numbers were 27 versus 23. Neither difference was statistically significant, and events were fewer than expected.[4]

The trial that can answer the heart question, TRIUMPH-Outcomes, is following about 10,000 adults with heart or kidney disease for about 5 years. Its estimated primary completion date is February 2029.[9]

What the trials can’t tell us yet

  • Long-term use: no published data go beyond about two years.
  • Rare events: the published abstracts and Lilly’s releases list common side effects. Detailed data on rare events seen with other drugs in this class, such as pancreatitis or gallbladder problems, will come with full regulatory review.
  • Excluded groups: trials screen people carefully. TRIUMPH-Outcomes, for example, excludes anyone with a history of pancreatitis, a personal or family history of medullary thyroid cancer or MEN 2, or severe gastroparesis.[9] Safety in those groups is untested.
  • The approved label: if retatrutide is approved, its label will set the warnings, and they may include risks not visible in these summaries.

Weighing risks against benefits

Safety is always judged against benefit. In TRIUMPH-1, average weight loss over 80 weeks was 17.6% to 25.0% on retatrutide versus 3.9% on placebo, and the drug also reduced knee osteoarthritis pain and breathing interruptions in sleep apnea.[1] Whether that benefit outweighs the side effects is a judgment regulators will make for the general population when they review the full data. For an individual, it is a conversation with a clinician.

The biggest risk: retatrutide sold outside trials

Retatrutide is not approved, and FDA says it cannot be used in compounding. The agency has warned companies selling retatrutide labeled “for research purposes” or “not for human consumption” with dosing instructions, and urges consumers not to buy these products, which it says are of unknown quality and may be harmful.[10]

A 2026 JAMA Network Open study of people describing their own unapproved retatrutide use online found a different symptom pattern from the trials: increased appetite, fatigue, increased energy, insomnia and raised heart rate were among the most reported. The authors cautioned that nobody could verify the products’ identity, purity or dose, so the findings cannot show cause.[11]

Questions to ask a clinician

  • Which approved medicine has the best safety record for someone like me?
  • Do I have conditions that trials of this drug class exclude, such as past pancreatitis?
  • Would I qualify for a retatrutide trial with proper monitoring?

For how retatrutide compares with an approved drug, see retatrutide vs tirzepatide and retatrutide vs semaglutide. The retatrutide dosage guide covers the doses tested.